Multiple Sclerosis Clinical Research Trials

Birmingham : Alabama Neurology Associates

A Safety Study of Combination Treatment With Avonex and Zocor in Relapsing Remitting Multiple Sclerosis

Cullman : GSK Investigational Site Updated

Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis

Cullman : Investigational Site Number 8965

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Cullman : North Central Neurology Associates, PC

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Cordova : Investigational Site Number 840005 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Phoenix : Research Site

A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis

Phoenix : St. Joseph’s Hospital and Medical Center

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Tucson : Research Site

A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis

Phoenix : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Phoenix :

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Phoenix : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Phoenix : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Phoenix : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Phoenix : Investigational Site Number 840003 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Phoenix : Investigational Site Number 8946

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Phoenix : Phoenix Neurological Associates, Ltd

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Scottsdale : Clinical Investigative Site 3132

ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis -Extension Study

Scottsdale : Neuromuscular Research Center

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Sun City : Arizona Neurological Institute

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Tempe : Clinical Research Advantage Inc.

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Tucson : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Tucson :

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Tucson : Clinical Investigative Site 3100

ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis -Extension Study

Tucson : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Tucson : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Tucson : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Tucson : Investigational Site Number 840001 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Little Rock : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Berkeley : Jordan Research and Education Institute

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Los Angeles : University of Southern California - Keck School of Medicine

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Aliso Viejo : Avanir Pharmaceuticals

PRISM Registry: Pseudobulbar Affect Registry Series

Berkeley : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Berkeley : Alta Bates Summit Medical Center

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Fontana : Private Practice

The Gilenya Pregnancy Registry

Fresno : Victoria Walton, MD

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Fresno : Neuro-Pain Medical Center, Inc.

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Fullerton : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Fullerton : Fullerton Neurology and Headache Center

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

La Jolla : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

La Jolla, : Coordinated Clinical Research

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Loma Linda : Loma Linda University Medical Center

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Long Beach : Collaborative NeuroScience Network, Inc.

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Los Angeles : USC MS Comprehensive Care Center

Clinical 15 Months Study Comparing Monthly Pulse ACTH (Acthar Gel) Therapy With Monthly Methylprednisolone (MP, Solumedrol) for Multiple Sclerosis (MS) Patients Who Are on Regular Beta-interferons (Avonex, Betaseron or Rebif)

Los Angeles : University of California Los Angeles

Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition

Los Angeles : USC MS Comprehensive Care Center & Research Group

Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities

Los Angeles : USC

Trial of Memantine for Cognitive Impairment in Multiple Sclerosis

Newport Beach :

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Newport Beach : Investigational Site Number 840048 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Newport Beach : Multiple Sclerosis Center of Southern California & Research

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Oceanside : Investigational Site Number 840011 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Pasadena :

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Sacramento : Clinical Investigative Site 3115

ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis -Extension Study

Sacramento : Sutter Institute for Medical Research

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Sacramento : University of California Davis Medical Center

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

San Diego : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

San Diego : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

San Francisco : University of California San Francisco

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Stanford : Clinical Investigative Site 3117

ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis -Extension Study

Temecula : Viking Clinical Research Center

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Torrance :

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Centennial : 1st International Clinical Research Center

Do you have Relapsing Remitting Multiple Sclerosis?

Denver : Research Site

A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis

Aurora : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Aurora : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Centennial : Research Site Updated

An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)

Centennial : Research Site

Safety Study of BIIB033 in Subjects With Multiple Sclerosis

Denver : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Denver : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Englewood : Colorado Neurological Institute

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Fort Collins : Investigational Site Number 840036 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Fort Collins : Investigational Site Number 8962

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Ft. Collins : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Ft. Collins : Research Site Updated

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

New London : Coastal Connecticut Research, LLC

Are You Currently Being Treated for a Relapsing Form of Multiple Sclerosis?

Pawcatuck : CNS Research of CT, Inc.

A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod 0.5 mg/day in Patients with Relapsing Forms of Multiple Sclerosis who are candidates for MS therapy change from Previous Disease Modifying Therapy (EPOC)

Hartford : Mount Sinai Rehabilitation Hospital

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Newark : Christiana Care Health Services

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Port Charlotte : Research Site

A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis

Sarasota : Research Site

A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis

St. Petersburg : Research Site

A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis

Tampa : Research Site

A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis

Bradenton : Research Site Updated

An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)

Bradenton : Brandenton Neurology, Inc.

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Hollywood : Sunrise Clinical Research, Inc.

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Jacksonville : University of Florida

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Lake Worth : Palm Beach Obestectrics and Gynecology

The Gilenya Pregnancy Registry

Maitland :

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Maitland : Investigational Site Number 840012 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Maitland : Investigational Site Number 8920

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Maitland : Neurology Associates, PA

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Maitland : Neurology Associates, PA

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Melbourne :

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Miami : University of Miami School of Medicine, Dept. of Neurology

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Naples : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Orlando :

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Ormond Beach : Investigational Site Number 840013 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Ormond Beach : Neurology Associates of Ormond Beach

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Ormond Beach : Neurology Associates of Ormond Beach

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Pompano Beach : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Pompano Beach : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Pompano Beach : Neurological Associates

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Pompano Beach : Neurological Associates

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Ponte Vedra : Neurologique Foundation, Inc.

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Port Charlotte : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Port Charlotte : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Port Orange : Progressive Medical Research

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Saint Petersburg : Suncoast Neuroscience Associates, Inc.

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Sarasota : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Sarasota :

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Sarasota : Clinical Investigative Site 3116

ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis -Extension Study

Sarasota : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Sarasota : Investigational Site Number 840008 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Sarasota : Roskamp Institute

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Sarasota : Negroski, Stein, Sutherland and Hanes Neurology

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

St. Petersburg : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

St. Petersburg : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

St. Petersburg : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

St. Petersburg : Investigational Site Number 840021 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

St. Petersburg : Investigational Site Number 8953

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

St. Petersburg : Suncoast Neuroscience Associates, Inc.

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

St. Petersburg : Suncoast Neuroscience Associates, Inc

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Sunrise : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Sunrise : Neurology Clinical Research

Masitinib in Patients With Primary Progressive or Relapse-free Secondary Multiple Sclerosis

Sunrise : GSK Investigational Site Updated

Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis

Tallahassee : AMO Corporation

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Tallahassee : Tallahassee Neurological Clinic, PA

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Tampa :

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Tampa : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Tampa : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Tampa : Investigational Site Number 840004 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Tampa : Investigational Site Number 840047 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Tampa : Axiom Clinical Research of Florida

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Vero Beach : MS Center of Vero Beach

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Vero Beach : The Multiple Sclerosis Center of Vero Beach

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Weston : Cleveland Clinic Florida

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Atlanta : NeuroTrials Research

Living with Multiple Sclerosis? Enrolling for a 96-week, non-placebo, comparative trial.

Atlanta : Neurotrials Research, Inc.

Living with Multiple Sclerosis? Enrolling for a 96-week, non-placebo, comparative trial.

Atlanta :

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Atlanta : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Atlanta : Investigational Site Number 8942

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Atlanta : Sheperd Center, Inc.

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Decatur : Neurostudies

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Honolulu : Leo Maher, MD

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Elk Grove Village : Alexian Brothers Hospital Network

A 6 month, randomized, active comparator, open-label, multi-center study to evaluate patient outcomes, safety and tolerability of Fingolimod (FTY720) 0.5mg/day in patients with relapsing remitting MS who are candidates for MS therapy change from previous disease modifying therapy (EPOC).

Flossmoor : South Suburban Neurology

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Barrington : Research Site Updated

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Chicago : Investigational Site Number 840034 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Chicago : Northwestern University

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Chicago : University of Chicago

Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis

Elk Grove Village : Investigational Site Number 840037 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Evanston : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Flossmoor : South Suburban Neurology

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Lake Barrington : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Lake Barrington : Research Site Updated

An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)

Lake Barrington : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Lake Barrington : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Lake Barrington : Northwest Neurology, LTD

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Northbrook :

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Northbrook : Consultants in Neurology

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Northbrook : Consultants in Neurology Ltd.

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Peoria : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Indianapolis : Research Site

A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis

Fort Wayne : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Ft. Wayne : Investigational Site Number 840025 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Ft. Wayne : Investigational Site Number 8914

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Indianapolis : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Indianapolis : Clinical Investigative Site 3101

ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis -Extension Study

Indianapolis : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Indianapolis : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Indianapolis : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Indianapolis : Investigational Site Number 8940

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Indianapolis : Josephson Wallack Munshower Neurology, P.C.

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Indianapolis : Indiana University

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Indianapolis : Josephson Wallack Munshower Neurology, PC

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Merrillville : Neuroscience Institute

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Des Moines : Ruan Neurology Research

Masitinib in Patients With Primary Progressive or Relapse-free Secondary Multiple Sclerosis

Des Moines : Mercy Ruan Neurology Clinic Res Ct.

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Des Moines : Iowa Health Des Moines

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Des Moines : Ruan Neurology Clinical Research Center

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Iowa City : Univeristy of Iowa/ VA Iowa City VA Medical Center

Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS)

Lenexa : Research Site

A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis

Lenexa : MidAmerica Neuroscience Institute

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Kansas City : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Kansas City : Clinical Investigative Site 3105

ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis -Extension Study

Kansas City : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Kansas City : The University of Kansas Medical Center

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Lenexa : Clinical Investigative Site 3107

ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis -Extension Study

Lenexa : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Lenexa : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Lenexa : Investigational Site Number 8929

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Lenexa : MidAmerica Neuroscience Institute

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Lenexa : Mid America Neuroscience Institute

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Topeka : Cotton O'Neil Clinical Research Institute

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Topeka : Precise Clinical Research

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Lexington : Research Site

A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis

Lexington : Associates in Neurology, P.S.C.

A Phase 3 study of PEGylated Interferon Beta-1a vs Placebo for subjects with Relapsing Remitting Multiple Sclerosis.

Lexington : Associates in Neurology, P.S.C.

A Phase 3 Study to determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex (Interferon-beta-1a) in Patients with Relapsing-Remitting Multiple Sclerosis.

Lexington : Associates in Neurology, P.S.C.

A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to evaluate the efficacy and safety of Ocrelizumab in comparison to Interferon Beta-1a (Rebif) in patients with Relapsing Multiple Sclerosis.

Lexington : Associates in Neurology, P.S.C.

Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Two Doses of Oral Dalfampridine Extended Release Tablets (5 mg and 10mg twice daily) in Patients with Multiple Sclerosis. Sponsored by: Acorda Therapeutics.

Lexington : Associates in Neurology, P.S.C.

Multicenter, open-labeled, randomized, active comparator research study to evaluate patient outcome, safety and tolerability of an investigational medicine in patients with Relapsing forms of Multiple Sclerosis and who are candidates for MS therapy change from previous disease modifying therapy.

Lexington : Associates in Neurology, P.S.C.

This trial is evaluating the safety and efficacy of an investigational oral medication for the treatment of spasticity in patients with multiple sclerosis (MS).

Lexington : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Lexington : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Lexington : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Lexington : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Lexington : Investigational Site Number 840042 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Lexington : Associates in Neurology

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Lexington : Associates in Neurology, PSC

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Louisville : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Louisville : Investigational Site Number 840033 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Louisville : University of Louisville (recruiting nationwide)

Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms

Louisville : Norton Healthcare, Inc.

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Shreveport : Louisiana State University

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Shreveport : Investigational Site Number 8922

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Baltimore : University of Maryland

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Baltimore : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Baltimore : University of Maryland

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Baltimore : University of Maryland, Maryland Center for Multiple Sclerosis

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Baltimore : Johns Hopkins University

Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis

Bethesda : Bethesda Neurology, LLC

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Bellingham : CNS Research of MA, Inc.

A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod 0.5 mg/day in Patients with Relapsing Forms of Multiple Sclerosis who are candidates for MS therapy change from Previous Disease Modifying Therapy (EPOC)

Boston : Brigham Women’s Hospital

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Boston : Caritas St. Elizabeth's Hospital

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Burlington : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Cambridge : Outcome Sciences, Inc

Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials

Lexington : Lahey Clinic

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Milford : Milford Regional Medical Center

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Newton : Newton-Wellesley Hospital

The Gilenya Pregnancy Registry

Springfield : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Springfield : Springfield Neurology Associates, LLC

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Springfield : Springfield Neurology Associates, LLC

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Worcester : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Worcester : Fallon Clinic at Worcester Medical Center

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Worchester : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Bingham Farms : Research Site

A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis

Bingham Farms : QUEST Research Institute

Multiple Sclerosis Spasticity Study

Ann Arbor : Universitly of Michigan

Masitinib in Patients With Primary Progressive or Relapse-free Secondary Multiple Sclerosis

Bingham Farms : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Bingham Farms : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Clinton Township : Investigational Site Number 840016 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Clinton TWP : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Detroit : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Detroit : Wayne State University

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Farmington Hills : Research Site Updated

An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)

Grand Rapids : Investigational Site Number 8955

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Grand Rapids : Saint Mary's Health Care

The Gilenya Pregnancy Registry

Traverse City : Investigational Site Number 8949

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Minneapolis : University of Minnesota

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Edina : Minneapolis Clinic of Neurology

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

St. Paul : Research Site Updated

Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy Volunteers

Hattiesburg : Hattiesburg Clinic Neurological Research Center

JCV Antibody program in patients with relapsing Multiple Sclerosis receiving or considering treatment with Tysabri

Hattiesburg : Hattiesburg Clinic Neurological Research Center

Study of the effect on cognitive performance, safety and tolerability of SAR110894D at doses of 0.5 mg, 2 mg and 5 mg/day for 24 weeks in patients with mild to moderate Alzheimer's Disease on stable donepezil therapy

Kansas City : Saint Luke's Hospital

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Kansas City : Research Neurology Associates

The Gilenya Pregnancy Registry

Saint Louis : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Springfield : St.John's Research Institute, Inc

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

St Louis : Investigational Site Number 840030 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

St Louis : Investigational Site Number 8937

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

St. Louis : Washington University (John L. Trotter MS Center)

Ampyra for Optic Neuritis in MS

Great Falls : Advanced Neurology Specialists

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Great Falls : Benefis Physician Associates

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Great Falls : Advanced Neurology Specialists

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Missoula : Investigational Site Number 840009 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Las Vegas : Cleveland Clinic - Las Vegas

The Gilenya Pregnancy Registry

Reno : Veterans Administration Medical Center

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Lebanon : Dartmouth Hitchcock Medical Center

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Toms River : Research Site

A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis

Freehold : CentraState Medical Center.

Masitinib in Patients With Primary Progressive or Relapse-free Secondary Multiple Sclerosis

New Brunswick : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Newark : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Newark : UMDNJ

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Newark : UMDNJ New Jersey Medical School

The Gilenya Pregnancy Registry

Teaneck : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Teaneck : Holy Name Hospital Multiple Sclerosis Center

Psychometric Validation of Cognitive Endpoints

Toms River : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Toms River : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

West Orange : Kessler Foundation

Psychometric Validation of Cognitive Endpoints

Albuquerque : Research Site

A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis

Albuquerque : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Albuquerque : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Albuquerque : Investigational Site Number 840023 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Albuquerque : Investigational Site Number 8951

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Buffalo : Jacobs Neurological Institute Buffalo General Hospital

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Mineola : Winthrop University Hospital Clinical Trials Center

Relapsing remitting multiple sclerosis

Mineola : Winthrop University Hospital Clinical Trials Center

Volunteers needed for a multiple sclerosis research study

New York : Judith Jaffe Multiple Sclerosis Center

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

New York : Biomedical Research Alliance of New York

Multiple Sclerosis - Adults

Patchogue : Research Site

A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis

Plainview : Research Site

A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis

Albany : Neurological Associates of Albany, PC

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Albany : Upstate Clinical Research, LLC

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Buffalo : Research Site

Controlled High Risk AVONEX® Multiple Sclerosis Prevention Study In Ongoing Neurological Surveillance

Buffalo : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Buffalo : University at Buffalo

Psychometric Validation of Cognitive Endpoints

Cleveland : Cleveland Clinic Foundation

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Latham : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Latham :

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Latham : Clinical Investigative Site # 3129

ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis -Extension Study

Latham : Clinical Investigative Site #3129

ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis -Extension Study

Latham : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Latham : Empire Neurology, PC

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

New York : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

New York : Investigational Site Number 8925

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

New York : NYC Hospital for Joint Diseases- MS Center

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

New York : Mount Sinai School of Medicine

Study to Evaluate Intravenous and Oral Steroids for Multiple Sclerosis Attacks

Patchogue : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Patchogue : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Patchogue : South Shore Neurologic Associates

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Patchogue : Comprehensive Multiple Sclerosis Care Center at South Shore Neurologic

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Plainview : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Plainview : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Plainview : Island Neurological Associates

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Plainview : Island Neurological Associates, PC

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Rochester : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Rochester : University of Rochester

Lubiprostone in Patients With Multiple Sclerosis Associated Constipation

Rochester : University of Rochester

Memantine for Spasticity in MS Patients

Rochester : University of Rochester Medical Center

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Rochester : University of Rochester

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Schenectady : Clinical Investigative Site 3127

ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis -Extension Study

Stony Brook : Clinical Investigative Site 3120

ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis -Extension Study

Stony Brook : Stony Brook University

Mindfulness Based Stress Reduction in Multiple Sclerosis (MS)

White Plains : Lauren S. Caruso

Psychometric Validation of Cognitive Endpoints

Asheville : Research Site

A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis

Chapel Hill : University of North Carolina

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Charlotte : PMG Research of Charlotte

MS: Have you been living with Multiple Sclerosis?

Hickory : PMG Research of Hickory

Do You Have Multiple Sclerosis (MS)?

Hickory : PMG Research of Hickory

MS: Have you been living with Multiple Sclerosis?

Winston-Salem : PMG Research of Winston-Salem

MS: Have you been living with Multiple Sclerosis?

Advance : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Advance :

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Advance : Investigational Site Number 840039 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Asheville : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Asheville : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Charlotte : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Charlotte :

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Charlotte : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Charlotte : Investigational Site Number 840027 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Charlotte : Neuroscience and Spine Institute/MS Center

Masitinib in Patients With Primary Progressive or Relapse-free Secondary Multiple Sclerosis

Charlotte : Investigational Site Number 8941

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Charlotte : The Neurological Institute, PA

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Charlotte : Metrolina Medical Research

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Charlotte : The Neurological Institute, PA

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Hickory : PMG Research of Hickory, LLC

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Raleigh : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Raleigh : Clinical Investigative Site 3119

ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis -Extension Study

Raleigh : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Raleigh : Raleigh Neurology Associates

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Winston Salem : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Winston-Salem : Research Site Updated

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Winston-Salem : PMG Research of Winston-Salem

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Bismarck : Legacy Pharma Research

MS - Central Neuropathic Pain due to Multiple Sclerosis

Bismarck : Legacy Pharma Research

MS - Central Neuropathic Pain due to Multiple Sclerosis

Bismark : Investigational Site Number 840006 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Fargo : Investigational Site Number 840007 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Grand Forks : Altru Health System Research Center

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Akron : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Akron :

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Akron : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Akron : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Bellevue : Northern Ohio Neuroscience, LLC

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Cincinnati : Clinical Investigative Site 3113

ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis -Extension Study

Cleveland : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Columbus : Clinical Investigative Site 3130

ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis -Extension Study

Columbus : Neurological Research Institute

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Columbus : Ohio State University, Columbus

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Dayton : Research Site Updated

An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)

Dayton : Investigational Site Number 840046 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Dayton : Investigational Site Number 8924

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Dayton : Neurology Specialists, Inc.

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Dayton : Neurology Specialists, Inc.

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Toledo : Investigational Site Number 840017 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Uniontown : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Uniontown : Research Site Updated

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Oklahoma City : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Oklahoma City : Mercy Multiple Sclerosis Center of Oklahoma Mercy Neuroscience Institute

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Portland : Providence St. Vincent Medical Center

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Corvallis : The Corvallis Clinic, P.C.

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Medford : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Portland : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Portland : Oregon Health and Science University

Dalfampridine for Imbalance in Multiple Sclerosis

Portland : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Portland : Providence Multiple Sclerosis Center

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Portland : Charleston Area Medical Center Health Education & Research Institute, Inc.

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Portland : Oregon Health Science University

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Abington :

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Allentown : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Allentown : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Greensburg : Westmoreland Neurology

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Greensburg : Westmoreland Neurology

The Gilenya Pregnancy Registry

Hershey : The Pennsylvania State University, Milton S. Hershey Medical Center

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Philadelphia : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Philadelphia : Investigational Site Number 8956

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Philadelphia : University of Pennsylvania Health System

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Philadelphia : Hospital of the University of Pennsylvania

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Philadelphia : Temple University Hospital

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Philadelphia : Hospital of Univ of Penn

The Gilenya Pregnancy Registry

Pittsburg : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Pittsburgh : Research Protocol Management Solutions

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Providence : CNS Research of RI, Inc.

A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod 0.5 mg/day in Patients with Relapsing Forms of Multiple Sclerosis who are candidates for MS therapy change from Previous Disease Modifying Therapy (EPOC)

Providence : The Neurology Foundation, Inc.

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Providence : CNS Research of RI, Inc.

Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis (SURPASS)

Providence : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Providence : Neurology Foundation

Masitinib in Patients With Primary Progressive or Relapse-free Secondary Multiple Sclerosis

Providence : Rhode Island Hospital

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Greenville :

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Franklin : Research Site

A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis

Franklin : Advanced Neurosciences Institute

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Nashville : Research Site

A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis

Cordova :

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Cordova : Neurology Clinic, PC

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Franklin : Research Site Updated

An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)

Franklin : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Franklin : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Franklin : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Franklin : Advanced Neurosciences Institute

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Knoxville : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Knoxville : Sibyl E. Wray, MD, Neurology, PC

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Memphis : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Nashville : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Nashville : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Nashville : Clinical Services Group Nashville

The Gilenya Pregnancy Registry

Round Rock : Investigational Site Number 840040 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Round Rock : Investigational Site Number 8905

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

San Antonio : Research Site

A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis

Dallas : Baylor Research Institute

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Dallas : University of Texas Southwestern

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Dallas : Texas Neurology, PA

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Dallas : UT Southwestern

Trial of Memantine for Cognitive Impairment in Multiple Sclerosis

Houston : Investigational Site Number 840014 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Houston : Kelsey Research Foundation

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Houston : Maxine Mesinger Multiple Sclerosis Clinic; Baylor College of Medicine

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Lubbock :

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Round Rock :

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Round Rock : Central Texas Neurology

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Round Rock : Central Texas Neurology Consultants, P.A.

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

San Antonio :

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

San Antonio : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

San Antonio : Investigational Site Number 840020 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

San Antonio : Innovative Clinical Trials, Bexar Diagnostic Medicine Assoc.

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

San Antonio : Centro Medical San Antonio

The Gilenya Pregnancy Registry

San Antonio : Integra Clinical Research

The Gilenya Pregnancy Registry

Sherman : Texoma Neurology Associates

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Salt Lake City : Lifetree Clinical Research

MS Treatment Study For New Dosage of an Already FDA-Approved MS Medication

Salt Lake City : Lifetree Clinical Research

MS Treatment Study For Those Not Content With Current Treatment

Salt Lake City : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Salt Lake City : Rocky Mountain MS Clinic

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Burlington : Clinical Investigative Site 3112

ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis -Extension Study

Burlington : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Burlington : Investigational Site Number 8930

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Burlington : Fletcher Allen Health Care

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Charlottesville : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Newport News : Hampton Roads Neurology

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Richmond : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Richmond : Neurological Associates

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Richmond : Virginia Commonwealth University Medical College of Virginia

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Vienna : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Vienna : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Vienna : Investigational Site Number 840032 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Vienna : MS Center of Greater Washington

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Seattle : Benaroya Research Institute at Virginia Mason

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)

Tacoma : Research Site

A Clinical Trial for Muscle Stiffness and/or Tightness due to Multiple Sclerosis

Kirkland : MS Center at Evergreen

A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis

Kirkland : Evergreen Healthcare

A Study to Test the Use of Duloxetine for Pain in MS

Kirkland : Clinical Investigative Site 3102

ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis -Extension Study

Kirkland : MS Center at Evergreen Healthcare

Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients With Multiple Sclerosis Taking Glatiramer Acetate

Kirkland : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Seattle : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Seattle : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Seattle : Investigational Site Number 8963

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Seattle : Pacific Medical Centers

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Seattle : Swedish Neuroscience Institute

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Seattle : Swedish Neuroscience Institute

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Seattle : MS Hub

Trial of Memantine for Cognitive Impairment in Multiple Sclerosis

Tacoma :

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Tacoma : XenoPort Clinical Site

Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)

Tacoma : XenoPort Clinical Site

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Tacoma : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Tacoma : Research Site Updated

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Tacoma : MultiCare Research Institute

Safety Study in Patients With Multiple Sclerosis Treated Fingoliomod or Other Approved Disease-modifying Therapies

Morgantown : United BioSource Corporation

Pregnancy Exposure Registry for Tysabri

Milwaukee : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Milwaukee : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Milwaukee : Aurora Saint Luke's Medical Center

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Ciudad Autónoma de Buenos Aires : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Godoy Cruz : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Rosario : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Adelaide : Merck Serono Research Site

Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.

Auchenflower : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Ballarat : Investigational Site Number 036009 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Bedford : Novartis Investigative Site

The Gilenya Pregnancy Registry

Bedford Park : Investigational Site Number 036008 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Bedford Park : Investigational Site Number 1408

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Box Hill : Research Site Updated

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Box Hill : Merck Serono Research Site

Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.

Bruce : Merck Serono Research Site

Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.

Camperdown : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Chatswood : Investigational Site Number 036005 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Chatswood : Merck Serono Research Site

Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.

Clayton : Merck Serono Research Site

Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.

Concord : Investigational Site Number 036003 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Fitzroy : Merck Serono Research Site

Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.

Footscray : Merck Serono Research Site

Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.

Geelong : Investigational Site Number 1405

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Geelong : Merck Serono Research Site

Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.

Gold Coast : Investigational Site Number 1409

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Heidelberg : Research Site Updated

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Heidelberg : Investigational Site Number 1404

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Heidelberg : Merck Serono Research Site

Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.

Heidelberg West : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Heidelberg West : Investigational Site Number 036001 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Hobart : Investigational Site Number 1407

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Hobart : Novartis Investigative Site

The Gilenya Pregnancy Registry

Kogarah : Investigational Site Number 036004 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Liverpool : Novartis Investigative Site

The Gilenya Pregnancy Registry

Nedlands : Research Site Updated

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

New Lambton : Investigational Site Number 036010 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Orange : Merck Serono Research Site

Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.

Parkville : Investigational Site Number 1401

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Perth : Merck Serono Research Site

Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.

St Leonards : Investigational Site Number 036002 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Subiaco : Novartis Investigative Site

The Gilenya Pregnancy Registry

Woollongong : Merck Serono Research Site

Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.

Graz : Investigational Site Number 040001 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Graz : Research Site Updated

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Innsbruck :

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Innsbruck : Research Site Updated

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Innsbruck : Investigational Site Number 4004

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Linz : Investigational Site Number 040004 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Linz : Investigational Site Number 4005

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Linz : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Many Locations :

Study Evaluating Betaferons® Safety and Tolerability In Pediatric Patients With Multiple Sclerosis

Salzburg : Investigational Site Number 040003 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Salzburg : Research Site Updated

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Vienna : Clinical Investigative Site 1101

ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis -Extension Study

Vienna : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Villach : Research Site Updated

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Wien : Investigational Site Number 040002 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Wien : Investigational Site Number 4001

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Antwerpen : Research Site

Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study

Brabant Wallon : Research Site

Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study

Brasschaat : Research Site

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS

Bruxelles : Research Site

Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study

Charleroi : Investigational Site Number 056005 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Esneux : Centre Hospitalier Universitaire de Liège Ourthe Ambléve

Efficacy of Clean Intermittent Catheterization in MS Patients With Bladder Dysfunction

Gent : Investigational Site Number 056004 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Hainaut : Research Site

Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study

Hasselt : Investigational Site Number 056003 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

La Louviere :

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Leuven : Investigational Site Number 056002 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Leuven : UZ Gasthuisberg

Efficacy of Clean Intermittent Catheterization in MS Patients With Bladder Dysfunction

Liege : Biogen Idec Investigative Site

A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients "TIMER" Study

Liege : Research Site

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS

Liège : Research Site

Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study

Limburg : Research Site

Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study

Luxembourg : Research Site

Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study

Many Locations : Updated

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Many Locations :

Study Evaluating Betaferons® Safety and Tolerability In Pediatric Patients With Multiple Sclerosis

Melsbroek : Research Site Updated

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Oost-Vlaanderen : Research Site

Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study

Sijsele-Damme : Investigational Site Number 056001 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

West-Vlaanderen : Research Site

Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study

Wilrijk : Research Site

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS

Many Locations : Updated

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Belo Horizonte : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Brasilia : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Campinas : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Joinville : Investigational Site Number 076009 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Passo Fundo : Investigational Site Number 076012 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Porto Alegre : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Recife : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Ribeirão Preto : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Rio de Janeiro : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Sao Paulo : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Sao Paulo : Investigational Site Number 076007 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Pleven :

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Pleven : Synthon investigational site 204

Efficacy and Safety of GTR in Comparison to Copaxone®

Pleven : Investigational Site Number 5312

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Plovdiv : Synthon investigational site 206

Efficacy and Safety of GTR in Comparison to Copaxone®

Sofia :

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Sofia :

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Sofia : Clinical Investigative Site # 1301

ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis -Extension Study

Sofia : Synthon investigational site 202

Efficacy and Safety of GTR in Comparison to Copaxone®

Sofia : Synthon investigational site 203

Efficacy and Safety of GTR in Comparison to Copaxone®

Sofia : Synthon investigational site 205

Efficacy and Safety of GTR in Comparison to Copaxone®

Sofia : Investigational Site Number 5304

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Sofia : Investigational Site Number 5309

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Sofia : Investigational Site Number 5303

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Sofia : Investigational Site Number 5307

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Varna : Synthon investigational site 201

Efficacy and Safety of GTR in Comparison to Copaxone®

Calgary : Foothills Medical Center

Avonex PEN Satisfaction and Patients Experience Clinical Trial

Calgary : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Calgary : Investigational Site Number 124005 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Calgary : Multiple Sclerosis Clinic

The Gilenya Pregnancy Registry

Cambridge : Research Site Updated

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Charny : MS Clinic

The Gilenya Pregnancy Registry

Edmonton : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Edmonton : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Edmonton : Investigational Site Number 124004 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Edmonton : Research Site Updated

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Edmonton : MS Clinic

The Gilenya Pregnancy Registry

Fleurimont : Estrie MS Clinic

The Gilenya Pregnancy Registry

Gatineau : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Gatineau : Clinique Neuro-Outaouais

Avonex PEN Satisfaction and Patients Experience Clinical Trial

Gatineau : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Gatineau : Investigational Site Number 124003 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Gatineau : Research Site Updated

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Gatineau : Clinique Neuro-Outaouais

The Gilenya Pregnancy Registry

Greenfield Park : Neuro Rive-Sud

Avonex PEN Satisfaction and Patients Experience Clinical Trial

Greenfield Park : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Greenfield Park : Investigational Site Number 5402

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Greenfield Park : Neuro Rive-Sud MS Clinic

The Gilenya Pregnancy Registry

Guelph : Norfolk Medical Clinic

Avonex PEN Satisfaction and Patients Experience Clinical Trial

Halifax : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Halifax : Dalhousie MS Research Unit

Avonex PEN Satisfaction and Patients Experience Clinical Trial

Halifax : Research Site Updated

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Halifax : Multiple Sclerosis Research Unit - Dalhousie

The Gilenya Pregnancy Registry

Hamilton : Hamilton MS Clinic, Hamilton Health Sciences

The Gilenya Pregnancy Registry

Kelowna : Satellite Clinic of UBC

The Gilenya Pregnancy Registry

Kingston : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Kingston : Investigational Site Number 124006 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Kingston : Kingston MS Clinic

The Gilenya Pregnancy Registry

London : London Health Sciences Centre

Avonex PEN Satisfaction and Patients Experience Clinical Trial

London : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

London : Research Site Updated

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

London : Investigational Site Number 5403

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

London : London MS Clinic

The Gilenya Pregnancy Registry

Montreal : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Montreal : Investigational Site Number 124007 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Montreal : Research Site Updated

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Montreal : Investigational Site Number 5409

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Montreal : Montreal Neurological Institute

The Gilenya Pregnancy Registry

Montréal : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Montréal : Hospital Notre-Dame - CHUM

The Gilenya Pregnancy Registry

Ottawa : Clinical Investigative Site 1400

ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis -Extension Study

Ottawa : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Ottawa : Investigational Site Number 124008 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Ottawa : Research Site Updated

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Ottawa : Investigational Site Number 5401

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Ottawa : MS Research Clinic

The Gilenya Pregnancy Registry

Prince George : Satellite Clinic of UBC, MS Clinic Prince George

The Gilenya Pregnancy Registry

Quebec : Research Site Updated

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Quebec : Investigational Site Number 5406

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Quebec : Clinique de maladies neuromusculaires et de sclérose en plaques IRDPQ

The Gilenya Pregnancy Registry

Quebec City : IRDPQ

Avonex PEN Satisfaction and Patients Experience Clinical Trial

Red Deer : Multiple Sclerosis Clinic

The Gilenya Pregnancy Registry

Regina : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Regina : Investigational Site Number 124002 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Riviere-Du-Loup : Research Site Updated

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Saint John : Saint John Regional Hospital

Avonex PEN Satisfaction and Patients Experience Clinical Trial

Saint John : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Saskatoon : Saskatoon City Hospital

The Gilenya Pregnancy Registry

Sherbrooke : Investigational Site Number 124001 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Sherbrooke : Investigational Site Number 5408

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

St. John's, Newfoundland and Labrador : MUN Hospital

Avonex PEN Satisfaction and Patients Experience Clinical Trial

St. John's, Newfoundland and Labrador : MS Clinic, Division of Neurology

The Gilenya Pregnancy Registry

Thunder Bay : Research Site Updated

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Thunder Bay : Thunder Bay MS Clinic

The Gilenya Pregnancy Registry

Toronto : Research Site Updated

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Toronto : Investigational Site Number 5410

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Toronto : Investigational Site Number 5404

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Toronto : MS Clinic

The Gilenya Pregnancy Registry

Toronto : Sunnybrook Health Sciences Centre

The Gilenya Pregnancy Registry

Trois-Rivières : Clinique de SP, Mauricie-Bois-Francs/Cœur du Québec

The Gilenya Pregnancy Registry

Vancouver : Vancouver Coastal Health: University of British Columbia Hospital

Effect of Aerobic Exercise on Side Effects of Disease Modifying Therapy With Subcutaneous Interferon-b1b in Patients With Multiple Sclerosis

Vancouver : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Vancouver : Research Site Updated

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Vancouver : MS Clinic UBC Hospital

Pharmacogenomics of Drug Safety in Multiple Sclerosis

Vancouver : MS Clinic

The Gilenya Pregnancy Registry

Vancouver : University of British Columbia

Treatment Adherence When Using RebiSmart™ in Relapsing Multiple Sclerosis Subjects

Victoria : Vancouver Island MS Clinic

The Gilenya Pregnancy Registry

Winnipeg :

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Winnipeg : Health Sciences Centre Multiple Sclerosis Clinic

Efficacy and Safety Evaluation of Nabilone as Adjunctive Therapy to Gabapentin for the Management of Neuropathic Pain in Multiple Sclerosis

Winnipeg : Investigational Site Number 124009 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Winnipeg : Research Site Updated

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Winnipeg : MS Clinic

The Gilenya Pregnancy Registry

Santiago : Investigational Site Number 1525606

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Santiago : Investigational Site Number 1525601

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Santiago : Investigational Site Number 1525602

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Viña Del Mar : Investigational Site Number 1525605

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Many Locations : Updated

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Nanjing : Nanjing University Medical College Affiliated Drum Tower Hospital

Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica

Barranquilla : Investigational Site Number 170001 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Bogota : Investigational Site Number 170005 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Bogota : Investigational Site Number 170002 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Bogota : Investigational Site Number 170006 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Bogota : Investigational Site Number 170007 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Bucaramanga : Investigational Site Number 170004 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Many Locations : Updated

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Medellin : Investigational Site Number 170003 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Medellin : Investigational Site Number 170009 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Brno : Clinical Investigative Site # 1502

ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis -Extension Study

Brno : Research Site Updated

An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)

Brno : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Brno : Investigational Site Number 5801

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Brno : Research Site

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing Remitting Multiple Sclerosis

Brno-bohunice :

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Hradec Kralove : Research Site Updated

An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)

Hradec Kralove : Novartis Investigative Site

Effect of Multiple Infusions of AIN457 on Disease Activity in Relapsing-remitting Multiple Sclerosis

Hradec Kralove : Research Site

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing Remitting Multiple Sclerosis

Jihlava :

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Jihlava : Clinical Investigative Site 1506

ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis -Extension Study

Jihlava : Research Site Updated

An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)

Many Locations : Updated

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Olomouc : Clinical Investigative Site # 1504

ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis -Extension Study

Olomouc : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Olomouc : Investigational Site Number 5804

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Ostrava : Research Site Updated

An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)

Ostrava : Novartis Investigative Site

Effect of Multiple Infusions of AIN457 on Disease Activity in Relapsing-remitting Multiple Sclerosis

Ostrava - Poruba : Investigational Site Number 5805

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Ostrava-Moravska : Novartis Investigative Site

Effect of Multiple Infusions of AIN457 on Disease Activity in Relapsing-remitting Multiple Sclerosis

Pardubice :

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Pardubice : Research Site Updated

An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)

Poruba : Clinical Investigative Site # 1501

ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis -Extension Study

Praha : Clinical Investigative Site # 1500

ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis -Extension Study

Praha : Novartis Investigative Site

Effect of Multiple Infusions of AIN457 on Disease Activity in Relapsing-remitting Multiple Sclerosis

Praha 10 : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Praha 2 :

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Praha 2 : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Teplice : Clinical Investigative Site # 1503

ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis -Extension Study

Teplice : Novartis Investigative Site

Effect of Multiple Infusions of AIN457 on Disease Activity in Relapsing-remitting Multiple Sclerosis

Teplice : Research Site

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing Remitting Multiple Sclerosis

Aalborg : Novartis Investigative Site

The Gilenya Pregnancy Registry

Aarhus C : Investigational Site Number 208002 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Aarhus C : Investigational Site Number 6002

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Århus : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Copenhagen : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Esbjerg : Research Site

A Single-blinded, Controlled, Multi-centre Study of Effects of Exercise in Patients With Multiple Sclerosis

Esbjerg : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Glostrup : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Glostrup : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Glostrup : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

København Ø : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Odense : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Odense C : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Sønderborg : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Vejle : Research Site

A Single-blinded, Controlled, Multi-centre Study of Effects of Exercise in Patients With Multiple Sclerosis

Vejle : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Viborg : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Many Locations : Updated

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Many Locations : Updated

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Tallinn :

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Tallinn : Investigational Site Number 233002 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Tallinn : Investigational Site Number 6201

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Tallinn : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Tartu :

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Tartu : Investigational Site Number 233001 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Tartu : Investigational Site Number 6203

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Helsinki :

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Helsinki : Clinical Investigative Site 1600

ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis -Extension Study

Helsinki : Investigational Site Number 246003 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Helsinki : Investigational Site Number 6405

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Helsinki : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Helsinski : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Hyvinkaa : Clinical Investigative Site # 1601

ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis -Extension Study

Hyvinkää : Investigational Site Number 246006 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Jyväskylä : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Jyväskylä : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Many Locations :

Study Evaluating Betaferons® Safety and Tolerability In Pediatric Patients With Multiple Sclerosis

Oulu : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Oulu : Investigational Site Number 246004 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Pori : Investigational Site Number 246002 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Seinäjoki : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Tampere : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Tampere :

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Tampere :

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Tampere : Clinical Investigative Site 1603

ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis -Extension Study

Tampere : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Tampere : Investigational Site Number 246005 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Tampere : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Turku : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Turku :

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Turku : Clinical Investigative 1602

ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis -Extension Study

Turku : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Turku : Investigational Site Number 246001 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Turku : Investigational Site Number 6401

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Turku : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Agen : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Aix En Provence : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Amiens : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Amiens : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Angers : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Auxerre : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Avignon : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Bayonne : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Belfort : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Besancon : Investigational Site Number 6611

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Beziers : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Bobigny : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Bobigny : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Bordeaux : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Bordeaux :

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Bordeaux : Service de Neurologie - Pôle des Neurosciences Cliniques, CHU de Bordeaux.

Randomised Controlled Clinical Trial of Cognitive Rehabilitation in Multiple Sclerosis

Boulogne Sur Mer : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Bourdeaux : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Brest : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Caen :

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Caen Cedex 5 : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Calais : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Castelnau Le Lez : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Chambray Les Tours : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Cherbourg Octeville : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Clermont Ferrand : Hôpital Gabriel Montpied

Masitinib in Patients With Primary Progressive or Relapse-free Secondary Multiple Sclerosis

Clermont Ferrand Cedex 1 : Investigational Site Number 250010 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Clermont Ferrand Cedex 1 : Investigational Site Number 6601

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Clermont-ferrand :

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Clermont-ferrand : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Dijon : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Dijon Cedex : Investigational Site Number 6613

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Epinal : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Garches : Hopital Raymond Poincaré

Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis

Grenoble : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Haguenau : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

La Rochelle : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

La Seyne Sur Mer : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Le Kremlin Bicetre : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Le Mans : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Lille :

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Lille : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Lille : Hôpital Roger Salengro

Masitinib in Patients With Primary Progressive or Relapse-free Secondary Multiple Sclerosis

Lille Cedex : Investigational Site Number 6609

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Limoges : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Lomme : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

L'union : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Lyon : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Lyon : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Many Locations : Updated

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Marseille : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Marseille : Hopital de la conception

Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis

Marseille Cedex 9 : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Metz : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Montauban : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Montbeliard : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Montpellier : CHU Hôpital Gui de Chauliac Service de Neurologie B

A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly

Montpellier : Clinical Investigative Site 1701

ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis -Extension Study

Montpellier : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Montpellier : Hôpital Guy de Chauliac

Masitinib in Patients With Primary Progressive or Relapse-free Secondary Multiple Sclerosis

Montpellier Cedex 05 : Investigational Site Number 6604

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Montpellier Cedex 5 : Investigational Site Number 250004 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Mulhouse : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Nancy :

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Nancy : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Nancy Cedex : Investigational Site Number 250001 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Nancy Cedex : Investigational Site Number 6612

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Nantes : CHU Hotel Dieu

Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis

Nantes Cedex 01 : Investigational Site Number 250006 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Nantes Cedex 01 : Investigational Site Number 6605

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Nice : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Nice Cedex : Investigational Site Number 6602

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Nimes :

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Nimes : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Nimes : Investigational Site Number 6614

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Orleans : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Orsay : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Paris :

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Paris : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Paris : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Paris : Hopital Tenon

Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis

Paris Cedex 5 : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Pau : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Poissy : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Poitiers : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Pontoise : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Quimper : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Reims : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Roanne : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Rouen : CHU Rouen - Hopital Charles Nicolle

Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis

Sainte Foy Les Lyon : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Saumur : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

St Aubin Sur Scie : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Strasbourg :

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Strasbourg : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Strasbourg : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Strasbourg : Service de Radiologie 2, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg

Magnetic Resonance Imaging (MRI) Follow-up of Macrophagic Infiltration in MS Patients Treated With Tysabri

Strasbourg : Service de Médecine Nucléaire, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg

Magnetic Resonance Imaging (MRI) Follow-up of Macrophagic Infiltration in MS Patients Treated With Tysabri

Strasbourg : Service de Neurologie, Hôpital Civil, Hôpitaux Universitaires de Strasbourg

Magnetic Resonance Imaging (MRI) Follow-up of Macrophagic Infiltration in MS Patients Treated With Tysabri

Strasbourg Cedex : Investigational Site Number 6607

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Talant : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Toulouse : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Toulouse : CHU Toulouse - Hopital Rangueil

Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis

Toulouse Cedex 3 : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Tourcoing : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Tours : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Vichy : Novartis Investigative Site

Fingolimod -Response According to Coping - Evaluation

Tbilisi : XX

Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Asbach : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Bad Mergentheim : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Bad Mergentheim : Investigational Site Number 276009 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Bad Neustadt / Saale : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Bad Wilbad : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Baesweiler : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Bamberg : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Bamberg : Investigational Site Number 276020 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Bamberg : Research Site Updated

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Bamberg : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Bamberg : Novartis Investigative Site

Zoledronic Acid in MS-patients With Osteoporosis

Bayreuth : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Bayreuth : Investigational Site Number 276003 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Bayreuth : Research Site Updated

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Bayreuth : Investigational Site Number 6801

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Berlin : Clinical Investigative Site 1807

ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis -Extension Study

Berlin : Novartis Investigative Site

Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod

Berlin : Novartis Investigative Site

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Berlin : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Berlin : Investigational Site Number 276015 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Berlin : Investigational Site Number 276016 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Berlin : Investigational Site Number 276021 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Berlin : Investigational Site Number 276007 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Berlin : St. Hedwig Hospital, Department of Urology

Efficacy of Clean Intermittent Catheterization in MS Patients With Bladder Dysfunction

Berlin : NeuroCure Clinical Research Center, Charité Berlin

Flupirtine as Oral Treatment in Multiple Sclerosis

Berlin : Research Site Updated

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Berlin : Investigational Site Number 6805

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Berlin : Investigational Site Number 6810

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Berlin : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Berlin : Novartis Investigative Site

Zoledronic Acid in MS-patients With Osteoporosis

Bielefeld : Novartis Investigative Site

Zoledronic Acid in MS-patients With Osteoporosis

Bochum : Investigational Site Number 276017 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Bochum : Research Site

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS

Bochum : Novartis Investigative Site

The Gilenya Pregnancy Registry

Bochum : Novartis Investigative Site

Zoledronic Acid in MS-patients With Osteoporosis

Bogen : Novartis Investigative Site

Zoledronic Acid in MS-patients With Osteoporosis

Bonn : Investigational Site Number 276012 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Butzbach : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Dresden : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Dresden : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Dresden : Investigational Site Number 276005 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Dresden : Research Site

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS

Dresden : Research Site Updated

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Dresden : Novartis Investigative Site

Zoledronic Acid in MS-patients With Osteoporosis

Düsseldorf : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Düsseldorf : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Erbach : Investigational Site Number 276018 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Erbach : Investigational Site Number 6807

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Erfurt : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Erlangen : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Essen : Clinical Investigative Site 1802

ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis -Extension Study

Essen : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Frankfurt : Research Site

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS

Frankfurt : Research Site Updated

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Frankfurt Am Main : Investigational Site Number 276025 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Freiburg : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Freiburg : Investigational Site Number 276028 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Freiburg : Research Site

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS

Freiburg : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Göttingen : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Göttingen : University of Göttingen, Department of Neurology

Flupirtine as Oral Treatment in Multiple Sclerosis

Hamburg :

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Hamburg : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Hamburg : Investigational Site Number 276010 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Hamburg : Research Site Updated

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Hamburg : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Hannover : Investigational Site Number 6809

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Hannover : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Heidelberg : Novartis Investigative Site

Zoledronic Acid in MS-patients With Osteoporosis

Hennigsdorf : Investigational Site Number 276022 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Ingolstadt : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Jena : Research Site

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS

Kandel : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Kassel : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Kassel : Investigational Site Number 276024 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Kassel : Research Site Updated

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Kassel : Novartis Investigative Site

Zoledronic Acid in MS-patients With Osteoporosis

Köln : Investigational Site Number 6813

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Köln : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Leipzig :

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Leipzig : Investigational Site Number 276001 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Leipzig : Novartis Investigative Site

Zoledronic Acid in MS-patients With Osteoporosis

Leverkusen : Novartis Investigative Site

Zoledronic Acid in MS-patients With Osteoporosis

Ludwigshafen : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Ludwigshafen : Investigational Site Number 6804

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Mainz : Investigational Site Number 276013 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Many Locations :

Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)

Many Locations :

Study Evaluating Betaferons® Safety and Tolerability In Pediatric Patients With Multiple Sclerosis

Marburg : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Marburg : Research Site

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS

Marburg : Research Site Updated

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Minden : Investigational Site Number 276023 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Minden : Novartis Investigative Site

Zoledronic Acid in MS-patients With Osteoporosis

Muenster : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Munchen : Research Site Updated

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

München : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Munich :

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Munster : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Münster : Investigational Site Number 276002 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Münster : Investigational Site Number 6802

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Münster : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Oldenburg : Research Site Updated

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Osnabrück : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Regensburg :

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Regensburg : Investigational Site Number 6814

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Regensburg : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Rostock : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Siegen : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Siegen : Novartis Investigative Site

Zoledronic Acid in MS-patients With Osteoporosis

Stuttgart : Novartis Investigative Site

Zoledronic Acid in MS-patients With Osteoporosis

Teupitz : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Tübingen : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Tuebingen : Research Site Updated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS

Ulm : Clinical Investigative Site 1804

ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis -Extension Study

Ulm : Research Site

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS

Ulm : University of Ulm, Department of Neurology

Flupirtine as Oral Treatment in Multiple Sclerosis

Ulm : Investigational Site Number 6812

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Wermsdorf : Novartis Investigative Site

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Wiesbaden :

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Wiesbaden : Investigational Site Number 276008 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Wiesbaden : Investigational Site Number 6806

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Wuppertal : Investigational Site Number 276026 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Würzburg : Investigational Site Number 276011 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Athens :

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Athens : Henry Dunant Hospital - IRB

An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters

Athens : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Athens : Investigational Site Number 300001 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Athens : Investigational Site Number 300002 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Heraklion : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Heraklion : Investigational Site Number 300003 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Ioannina : Investigational Site Number 300004 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Larissa : Investigational Site Number 300005 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Thessaloniki :

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Thessaloniki : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Thessaloniki : Investigational Site Number 300006 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Budapest :

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Budapest :

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Budapest : Clinical Investigative Site 1904

ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis -Extension Study

Budapest : Clinical Investigative Site 1905

ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis -Extension Study

Budapest : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Budapest : Investigational Site Number 348006 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Budapest : Investigational Site Number 348010 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Budapest : Investigational Site Number 348002 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Budapest : Investigational Site Number 7103

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Budapest : Investigational Site Number 7101

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Budapest : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Debrecen : Research Site Updated

An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)

Eger : Research Site Updated

An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)

Eger : Investigational Site Number 348009 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Esztergom : Clinical Investigative Site 1900

ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis -Extension Study

Esztergom : Research Site Updated

An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)

Esztergom : Investigational Site Number 348003 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Gyor : Clinical Investigative Site 1902

ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis -Extension Study

Gyor : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Kaposvár : Investigational Site Number 348008 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Kecskemét : Investigational Site Number 348004 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Miskolc : Clinival Investigative Site # 1901

ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis -Extension Study

Nyiregyhaza : Research Site Updated

An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)

Nyíregyháza : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Pécs :

A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Pécs : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Szeged : Investigational Site Number 348001 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Szeged : Research Site

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Szekesfehervar : Investigational Site Number 348005 Updated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Székesfehérvár : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Veszprem : Research Site Updated

An Immunogenicity and Pharmacokinetics (PK) Study of DAC HYP Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)

Veszprém : Research Site

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Veszprém : Investigational Site Number 348011 Updated<